Second-line treatment for primary central nervous system lymphoma.
about
18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System LymphomasTreatment options for central nervous system lymphomas in immunocompetent patients.Late relapse in primary central nervous system lymphoma: clonal persistenceTemozolomide as salvage treatment in primary brain lymphomas.Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.Primary CNS lymphoma: a clinician's guide.Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Salvage therapy for refractory AIDS-related primary central nervous system lymphoma.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.Primary CNS Lymphoma.
P2860
Q30654615-09E3D264-C38F-4A25-97E4-989F9F2CAFEAQ33347138-E3D6783C-A6EE-4447-82A8-40F97AC37FF4Q33396041-27131C96-E8B3-4A44-9CA5-8E5D80FBBFA5Q33427856-AA4BF299-FD58-42E6-A40C-53F086138AFCQ33510785-F250D735-705C-4E4E-B33B-D7976C4360C9Q34977369-0CAF4262-794F-4B48-8541-11D24287F710Q36610071-93544882-AAFE-49CE-96FD-0515E5599A96Q36805893-B3A9C076-86D3-49C3-896C-65D3020B1814Q37183305-B3BAE9C1-2E6B-4938-8FF7-E0BF6D5FCCDAQ38053442-2121D8FB-D91C-4ADB-B5D8-0EB362D13766Q38741324-1BD1F75A-52D4-4D4E-8A46-6D8467DD58ACQ40196257-B392A611-79F4-4DEF-B10A-7B5286C7B402Q41139081-7E54A6B7-626D-4979-8DC4-52715BD7FF48Q42632859-EDD67238-ED43-4039-AF81-20F3DC5AD5A4Q47692369-92EE379F-DFC5-4FD6-8EEB-14D720DB8220Q48114320-688615A5-007E-4A32-8838-2A0178CEC819Q48132084-04678C3E-1D9F-44ED-B38B-6428423AD027Q51841565-87C6FEAB-FA1D-487C-B511-60B9775603EA
P2860
Second-line treatment for primary central nervous system lymphoma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Second-line treatment for primary central nervous system lymphoma.
@ast
Second-line treatment for primary central nervous system lymphoma.
@en
Second-line treatment for primary central nervous system lymphoma.
@nl
type
label
Second-line treatment for primary central nervous system lymphoma.
@ast
Second-line treatment for primary central nervous system lymphoma.
@en
Second-line treatment for primary central nervous system lymphoma.
@nl
prefLabel
Second-line treatment for primary central nervous system lymphoma.
@ast
Second-line treatment for primary central nervous system lymphoma.
@en
Second-line treatment for primary central nervous system lymphoma.
@nl
P2093
P2860
P921
P356
P1476
Second-line treatment for primary central nervous system lymphoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690083
P407
P577
1999-02-01T00:00:00Z
P5875
P6179
1041883342